Background. Dedicator of cytokinesis 2 (DOCK2) deficiency is a rare autosomal recessive combined immunodeficiency presenting with very early onset, severe bacterial and viral infections. In DOCK2 deficiency; T, B and NK cell numbers are decreased and functions are impaired resulting in severe atrophy of secondary lymphoid tissues. The aim of this report is to provide information on clinical and laboratory features and hematopoietic stem cell transplantation (HSCT) outcomes of a DOCK2 deficient patient. The patient was diagnosed by using a targeted next generation sequencing primary immunodeficiency (PID) panel. Lymphocyte subsets were measured by flow-cytometry. Case. Here, we describe a patient with DOCK2 deficiency presented with severe combined immunodeficiency. He underwent HSCT without conditioning regimen before the genetic diagnosis and developed hemophagocytic lymphohistiocytosis(HLH) due to Epstein-Barr virus (EBV) infection. Conclusions. Genetic testing is necessery for early diagnosis of DOCK2 deficiency. The curative treatment should be HSCT soon after diagnosis
___
1. Gotoh K, Tanaka Y, Nishikimi A, et al. Differential requirement for DOCK2 in migration of plasmacytoid dendritic cells versus myeloid dendritic cells. Blood 2008; 111: 2973-2976. https:// doi.org/10.1182/blood-2007-09-112169
2. Nishikimi A, Kukimoto-Niino M, Yokoyama S, Fukui Y. Immune regulatory functions of DOCK family proteins in health and disease. Exp Cell Res 2013; 319: 2343-2349. https://doi.org/10.1016/j. yexcr.2013.07.024
3. Sanui T, Inayoshi A, Noda M, et al. DOCK2 is essential for antigen-induced translocation of TCR and lipid rafts, but not PKC-θ and LFA-1, in T cells. Immunity 2003; 19: 119-129. https://doi.org/10.1016/ S1074-7613(03)00169-9
4. Moens L, Gouwy M, Bosch B, et al. Human DOCK2 deficiency: report of a novel mutation and evidence for neutrophil dysfunction. J Clin Immunol 2019; 39: 298-308. https://doi.org/10.1007/s10875-019-00603-w
5. Dobbs K, Domínguez Conde C, Zhang SY, et al. Inherited DOCK2 deficiency in patients with early- onset invasive infections. N Engl J Med 2015; 372: 2409-2422. https://doi.org/10.1056/NEJMoa1413462
6. Alosaimi MF, Shendi H, Beano A, et al. T cell mitochondrial dysfunction and lymphopenia in DOCK2-deficient patients. J Allergy Clin Immunol 2019; 144: 306-309. https://doi.org/10.1016/j. jaci.2019.02.020
7. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405-423. https://doi.org/10.1038/ gim.2015.30
8. Faitelson Y, Grunebaum E. Hemophagocytic lymphohistiocytosis and primary immune deficiency disorders. Clin Immunol 2014; 155: 118- 125. https://doi.org/10.1016/j.clim.2014.09.008
9. Sinno MG, Rosen D, Wittler R. Concomitant presentation of hemophagocytic lymphohistiocytosis and posttransplant lymphoproliferative disease-like lymphoma in a mildly immunosuppressed leukemia patient: an unusual association. Pediatr Blood Cancer 2016; 63: 1474-1476. https://doi.org/10.1002/ pbc.26033
10. Asano T, Kogawa K, Morimoto A, et al. Hemophagocytic lymphohistiocytosis after hematopoietic stem cell transplantation in children: a nationwide survey in Japan. Pediatr Blood Cancer 2012; 59: 110-114. https://doi.org/10.1002/pbc.23384
11. Ali S, AlThubaiti S, Renzi S, et al. Hemophagocytic lymphohistiocytosis is a sign of poor outcome in pediatric Epstein-Barr virus-associated post- transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Pediatr Transplant 2019; 23: e13319. https://doi. org/10.1111/petr.13319
12. Chellapandian D, Das R, Zelley K, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol 2013; 162: 376-382. https://doi.org/10.1111/bjh.12386
13. Gotoh K, Tanaka Y, Nishikimi A, et al. Selective control of type I IFN induction by the Rac activator DOCK2 during TLR-mediated plasmacytoid dendritic cell activation. J Exp Med 2010; 207: 721- 730. https://doi.org/10.1084/jem.20091776